Bioinformatics Seminar
Time:
Venue: Na
13 June 2017
NaTargeting G9a and EZH2 for the treatment of solid tumours
Jason LeeQIMR Berghofer
There is now strong evidence that epigenetic alterations are key drivers of cancer progression. G9a and EZH2 are epigenetic regulators that methylate histone H3 causing gene repression and participate in diverse cellular functions. Both G9a and EZH2 are genetically deregulated in a variety of tumour-types ; and can silence tumour suppressor genes and therefore are important for carcinogenesis. Hypoxia is recognised to be an adverse factor in tumour growth and metastasis. EZH2 transcript level is increased while G9a protein accumulation occurs in hypoxic conditions. I will present data on the functional role of G9a and EZH2 in regulating gene expression ; the prognostic value of G9a-suppressed gene signature and the potential of small molecule inhibitors of these two enzymes as novel therapy for aggressive cancers.;Davis Auditorium
Visit the biography of the speaker